
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF N DESMETHYLVENLAFAXINE</TD><TD>BC SATISFIED ASSERTION_508, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF 1,3 DIMETHYLURIC ACID</TD><TD>BC SATISFIED ASSERTION_28, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP1,3 DIMETHYLURIC ACIDE1 CONTROLS FORMATION OF 1,3 DIMETHYLURIC ACID</TD><TD>BC SATISFIED ASSERTION_175, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPO DESMETHYLVENLAFAXINED6 CONTROLS FORMATION OF O DESMETHYLVENLAFAXINE</TD><TD>BC SATISFIED ASSERTION_739, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP9 HYDROXYRISPERIDONED6 CONTROLS FORMATION OF 9 HYDROXYRISPERIDONE</TD><TD>BC SATISFIED ASSERTION_996, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP4 HYDROXYATOMOXETINED6 CONTROLS FORMATION OF 4 HYDROXYATOMOXETINE</TD><TD>BC SATISFIED ASSERTION_304, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DESMETHYLROSUVASTATINC9 CONTROLS FORMATION OF N DESMETHYLROSUVASTATIN</TD><TD>BC SATISFIED ASSERTION_244, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DESMETHYLATOMOXETINEC19 CONTROLS FORMATION OF N DESMETHYLATOMOXETINE</TD><TD>BC SATISFIED ASSERTION_487, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPHYDROXYBUPROPIONB6 CONTROLS FORMATION OF HYDROXYBUPROPION</TD><TD>BC SATISFIED ASSERTION_1186, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP1A3 METHYLXANTHINE CONTROLS FORMATION OF 3 METHYLXANTHINE</TD><TD>BC SATISFIED ASSERTION_264, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2</TD><TD>CYP1A3 METHYLXANTHINE CONTROLS FORMATION OF 3 METHYLXANTHINE, THEOPHYLLINE HAS METABOLITE 3 METHYLXANTHINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION VIA CYP2B6</TD><TD>CYPHYDROXYBUPROPIONB6 CONTROLS FORMATION OF HYDROXYBUPROPION, BUPROPION HAS METABOLITE HYDROXYBUPROPION, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>CYPN DESMETHYLATOMOXETINEC19 CONTROLS FORMATION OF N DESMETHYLATOMOXETINE, ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>CYPN DESMETHYLROSUVASTATINC9 CONTROLS FORMATION OF N DESMETHYLROSUVASTATIN, ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>CYP4 HYDROXYATOMOXETINED6 CONTROLS FORMATION OF 4 HYDROXYATOMOXETINE, ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>CYP9 HYDROXYRISPERIDONED6 CONTROLS FORMATION OF 9 HYDROXYRISPERIDONE, RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>CYPO DESMETHYLVENLAFAXINED6 CONTROLS FORMATION OF O DESMETHYLVENLAFAXINE, VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP2E1 DIMETHYLURIC ACID VIA CYP2E1</TD><TD>CYP1,3 DIMETHYLURIC ACIDE1 CONTROLS FORMATION OF 1,3 DIMETHYLURIC ACID, THEOPHYLLINE HAS METABOLITE 1,3 DIMETHYLURIC ACID, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>CYP3A4 CONTROLS FORMATION OF 1,3 DIMETHYLURIC ACID, THEOPHYLLINE HAS METABOLITE 1,3 DIMETHYLURIC ACID, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>CYP3A4 CONTROLS FORMATION OF N DESMETHYLVENLAFAXINE, VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, ZILEUTON INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, VERAPAMIL INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, VEMURAFENIB INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, TICLOPIDINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, TERBINAFINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, PROPAFENONE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYLPROPANOLAMINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, PHENYLPROPANOLAMINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLOXACIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, NORFLOXACIN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHOXSALEN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, METHOXSALEN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>FAMOTIDINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, FAMOTIDINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>DISULFIRAM INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, DISULFIRAM INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, CIPROFLOXACIN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, CIMETIDINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, CAFFEINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, AMIODARONE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALLOPURINOL INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, ALLOPURINOL INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>ACYCLOVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 3 METHYLXANTHINE VIA CYP1A2</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, ACYCLOVIR INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE INHIBITS TRANSFORMATION OF BUPROPION TO HYDROXYBUPROPION VIA CYP2B6</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION VIA CYP2B6, TICLOPIDINE INHIBITS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRASUGREL INHIBITS TRANSFORMATION OF BUPROPION TO HYDROXYBUPROPION VIA CYP2B6</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION VIA CYP2B6, PRASUGREL INHIBITS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOPIDOGREL INHIBITS TRANSFORMATION OF BUPROPION TO HYDROXYBUPROPION VIA CYP2B6</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION VIA CYP2B6, CLOPIDOGREL INHIBITS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, VORICONAZOLE N OXIDE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, VORICONAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, TICLOPIDINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, OMEPRAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL SULFONE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, MODAFINIL SULFONE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, MODAFINIL INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, KETOCONAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, FLUVOXAMINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, FLUOXETINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, FLUCONAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>FELBAMATE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, FELBAMATE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ETRAVIRINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, ETRAVIRINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESOMEPRAZOLE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, ESOMEPRAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, CIMETIDINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARMODAFINIL INHIBITS TRANSFORMATION OF ATOMOXETINE TO N DESMETHYLATOMOXETINE VIA CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, ARMODAFINIL INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, ZAFIRLUKAST INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, VORICONAZOLE N OXIDE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, VORICONAZOLE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>TIGECYCLINE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, TIGECYCLINE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERIFLUNOMIDE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, TERIFLUNOMIDE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>SULFINPYRAZONE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, SULFINPYRAZONE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>OXANDROLONE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, OXANDROLONE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>MICONAZOLE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, MICONAZOLE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>METRONIDAZOLE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, METRONIDAZOLE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, FLUVASTATIN INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, FLUCONAZOLE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>ETRAVIRINE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, ETRAVIRINE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>COTRIMOXAZOLE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, COTRIMOXAZOLE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAPECITABINE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, CAPECITABINE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF ROSUVASTATIN TO N DESMETHYLROSUVASTATIN VIA CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, AMIODARONE INHIBITS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, VERAPAMIL INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, VENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, VEMURAFENIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, TERBINAFINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, TELITHROMYCIN INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, SERTRALINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, RITONAVIR INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, RANOLAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, RANITIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, QUINIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, PROPAFENONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, PAZOPANIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, PAROXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, METHADONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, IMATINIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, ILOPERIDONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, HYDROXYCHLOROQUINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDRALAZINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, HYDRALAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, FLUOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FEBUXOSTAT INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, FEBUXOSTAT INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, DULOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, DIPHENHYDRAMINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, DILTIAZEM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, DESVENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOBAZAM INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, CLOBAZAM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, CINACALCET INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, CIMETIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, CELECOXIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, BUPROPION INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF ATOMOXETINE TO CYP2D6 HYDROXYATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, AMIODARONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, VERAPAMIL INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, VENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, VEMURAFENIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, TERBINAFINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, TELITHROMYCIN INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, SERTRALINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, RITONAVIR INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, RANOLAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, RANITIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, QUINIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, PROPAFENONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, PAZOPANIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, PAROXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, METHADONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, IMATINIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, ILOPERIDONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, HYDROXYCHLOROQUINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDRALAZINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, HYDRALAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, FLUOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FEBUXOSTAT INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, FEBUXOSTAT INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, DULOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, DIPHENHYDRAMINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, DILTIAZEM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, DESVENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOBAZAM INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, CLOBAZAM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, CINACALCET INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, CIMETIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, CELECOXIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, BUPROPION INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, AMIODARONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, VERAPAMIL INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, VENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, VEMURAFENIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, TERBINAFINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, TELITHROMYCIN INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, SERTRALINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, RITONAVIR INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, RANOLAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, RANITIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, QUINIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, PROPAFENONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, PAZOPANIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, PAROXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, METHADONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, IMATINIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, ILOPERIDONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, HYDROXYCHLOROQUINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDRALAZINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, HYDRALAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, FLUOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FEBUXOSTAT INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, FEBUXOSTAT INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, DULOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, DIPHENHYDRAMINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, DILTIAZEM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, DESVENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOBAZAM INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, CLOBAZAM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, CINACALCET INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, CIMETIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, CELECOXIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, BUPROPION INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF VENLAFAXINE TO O DESMETHYLVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, AMIODARONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ZILEUTON INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, TELITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELAPREVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, TELAPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, RANITIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, QUINIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, POSACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, PAZOPANIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, NILOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, NELFINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, LAPATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ISONIAZID INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ISONIAZID INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, IMATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FOSAMPRENAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, FOSAMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, FLUVOXAMINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, FLUOXETINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, DRONEDARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, CYCLOSPORINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CRIZOTINIB INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, CRIZOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, CONIVAPTAN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, CIPROFLOXACIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>BOCEPREVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, BOCEPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>BICALUTAMIDE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, BICALUTAMIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AZITHROMYCIN INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, AZITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, APREPITANT INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMPRENAVIR INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, AMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM INHIBITS TRANSFORMATION OF THEOPHYLLINE TO 1,3 DIMETHYLURIC ACID VIA CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, ALPRAZOLAM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, ZILEUTON INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, TELITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELAPREVIR INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, TELAPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, RANITIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, QUINIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, POSACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, PAZOPANIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, NILOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, NELFINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, LAPATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ISONIAZID INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, ISONIAZID INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, IMATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FOSAMPRENAVIR INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, FOSAMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, FLUVOXAMINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, FLUOXETINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, DRONEDARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, CYCLOSPORINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CRIZOTINIB INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, CRIZOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, CONIVAPTAN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, CIPROFLOXACIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>BOCEPREVIR INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, BOCEPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>BICALUTAMIDE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, BICALUTAMIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AZITHROMYCIN INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, AZITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, APREPITANT INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMPRENAVIR INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, AMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM INHIBITS TRANSFORMATION OF VENLAFAXINE TO N DESMETHYLVENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, ALPRAZOLAM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         '3-METHYLXANTHINE 'THEOPHYLLINE 'CYP2E1)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         '3-METHYLXANTHINE 'THEOPHYLLINE 'CYP3A4)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         '1,3-DIMETHYLURIC-ACID 'THEOPHYLLINE 'CYP1A2)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         'N-DESMETHYLATOMOXETINE 'ATOMOXETINE 'CYP2D6)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         '4-HYDROXYATOMOXETINE 'ATOMOXETINE 'CYP2C19)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         'O-DESMETHYLVENLAFAXINE 'VENLAFAXINE 'CYP3A4)</TD></TR>
<TR><TD>(EFFECT-ON-1-OF-MODULATING-THE-CLEARANCE-OF-2-VIA-3-IS-NON-AMBIGUOUS
         'N-DESMETHYLVENLAFAXINE 'VENLAFAXINE 'CYP2D6)</TD></TR>
<TR><TD>PKI-1</TD><TD>ZILEUTON EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ZILEUTON INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, TELITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, TELAPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, RANITIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, QUINIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, POSACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, PAZOPANIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, NILOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, NELFINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, LAPATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ISONIAZID INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, IMATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, FOSAMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, FLUVOXAMINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, FLUOXETINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, DRONEDARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, CYCLOSPORINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, CRIZOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, CONIVAPTAN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, CIPROFLOXACIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, BOCEPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, BICALUTAMIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, AZITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, APREPITANT INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, AMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM EFFECTS AN INCREASE IN THEOPHYLLINE METHYLXANTHINE BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>EFFECT ON CYP3A4 METHYLXANTHINE OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP3A4 IS NON AMBIGUOUS, ALPRAZOLAM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, ZILEUTON INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, VERAPAMIL INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, VEMURAFENIB INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, TICLOPIDINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, TERBINAFINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, PROPAFENONE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, PHENYLPROPANOLAMINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, NORFLOXACIN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, METHOXSALEN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, FAMOTIDINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, DISULFIRAM INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, CIPROFLOXACIN INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, CIMETIDINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, CAFFEINE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, AMIODARONE INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, ALLOPURINOL INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR EFFECTS AN INCREASE IN 1,THEOPHYLLINE DIMETHYLURIC ACID BY REDUCING CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>EFFECT ON 1,CYP1A2 DIMETHYLURIC ACID OF MODULATING THE CLEARANCE OF THEOPHYLLINE VIA CYP1A2 IS NON AMBIGUOUS, ACYCLOVIR INHIBITS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, VERAPAMIL INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, VENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, VEMURAFENIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, TERBINAFINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, TELITHROMYCIN INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, SERTRALINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, RITONAVIR INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, RANOLAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, RANITIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, QUINIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, PROPAFENONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, PAZOPANIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, PAROXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, METHADONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, IMATINIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, ILOPERIDONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, HYDROXYCHLOROQUINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, HYDRALAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, FLUOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, FEBUXOSTAT INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, DULOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, DIPHENHYDRAMINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, DILTIAZEM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, DESVENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, CLOBAZAM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, CINACALCET INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, CIMETIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, CELECOXIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, BUPROPION INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE EFFECTS AN INCREASE IN N DESMETHYLATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2D6 IS NON AMBIGUOUS, AMIODARONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, VORICONAZOLE N OXIDE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, VORICONAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, TICLOPIDINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, OMEPRAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, MODAFINIL SULFONE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, MODAFINIL INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, KETOCONAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, FLUVOXAMINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, FLUOXETINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, FLUCONAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, FELBAMATE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, ETRAVIRINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, ESOMEPRAZOLE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, CIMETIDINE INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL EFFECTS AN INCREASE IN CYP2C19 HYDROXYATOMOXETINE BY REDUCING CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>EFFECT ON 4 HYDROXYATOMOXETINE OF MODULATING THE CLEARANCE OF ATOMOXETINE VIA CYP2C19 IS NON AMBIGUOUS, ARMODAFINIL INHIBITS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, ZILEUTON INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, TELITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, TELAPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, RANITIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, QUINIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, POSACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, PAZOPANIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, NILOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, NELFINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, LAPATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, ISONIAZID INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, IMATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, FOSAMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, FLUVOXAMINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, FLUOXETINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, DRONEDARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, CYCLOSPORINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, CRIZOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, CONIVAPTAN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, CIPROFLOXACIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, BOCEPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, BICALUTAMIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, AZITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, APREPITANT INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, AMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM EFFECTS AN INCREASE IN O DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>EFFECT ON O DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP3A4 IS NON AMBIGUOUS, ALPRAZOLAM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, VERAPAMIL INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, VENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, VEMURAFENIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, TERBINAFINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, TELITHROMYCIN INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, SERTRALINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, RITONAVIR INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, RANOLAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, RANITIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, QUINIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, PROPAFENONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, PAZOPANIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, PAROXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, METHADONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, IMATINIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, ILOPERIDONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, HYDROXYCHLOROQUINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, HYDRALAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, FLUOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, FEBUXOSTAT INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, DULOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, DIPHENHYDRAMINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, DILTIAZEM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, DESVENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, CLOBAZAM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, CINACALCET INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, CIMETIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, CELECOXIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, BUPROPION INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE EFFECTS AN INCREASE IN N DESMETHYLVENLAFAXINE BY REDUCING CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>EFFECT ON N DESMETHYLVENLAFAXINE OF MODULATING THE CLEARANCE OF VENLAFAXINE VIA CYP2D6 IS NON AMBIGUOUS, AMIODARONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZOSUQUIDAR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZOLPIDEM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZALEPLON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VALSPODAR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VALPROATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TROLEANDOMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIMETHOPRIM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIFLUOPERAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRAZODONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRANYLCYPROMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOPOTECAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOLVAPTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TIZANIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TIPRANAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TIGECYCLINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TICAGRELOR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTHIXENE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTEPA IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIABENDAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TESTOSTERONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TENIPOSIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TELAPREVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TALINOLOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TACROLIMUS IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULPHAPHENAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFINPYRAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFAMETHOXAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFAMETHIZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SITAGLIPTIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIROLIMUS IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SILDENAFIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SAXAGLIPTIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SAQUINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RIFAMPIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RESERPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RAMELTEON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RABEPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUINUPRISTIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUININE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUERCETIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROPOXYPHENE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROMETHAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PRASUGREL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PITAVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PIOGLITAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PIMOZIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PILOCARPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYLPROPANOLAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENCYCLIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENACETIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PACLITAXEL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OXYCARBAZEPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OXCARBAZEPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OXANDROLONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLOXACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NICARDIPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NEBIVOLOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MOLINDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIFEPRISTONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDODRINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MICONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MEXILETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METRONIDAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METHOXSALEN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MEPHENYTOIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MELATONIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MARAVIROC IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LURASIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LOVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LITHIUM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LEFLUNOMIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ISONIAZID IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>IRINOTECAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>INDOMETHACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>IBUPROFEN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDRALAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HALOPERIDOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FOSAMPRENAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUTICASONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOROURACIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLECAINIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FEXOFENADINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FELBAMATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FEBUXOSTAT IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FAMOTIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EZETIMIBE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EVEROLIMUS IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ETRAVIRINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ETHANOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ESOMEPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ELTROMBOPAG IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ELACRIDAR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DROPERIDOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DOXORUBICIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DISULFIRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIHYDROERGOTAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIGOXIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIETHYLDITHIOCARBAMATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESLORATADINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESIPRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DELAVIRDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DASATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DARUNAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DARIFENACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DANAZOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN ETEXILATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CRIZOTINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>COTRIMOXAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>COLCHICINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOTRIMAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOPIDOGREL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOMIPRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOBAZAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORZOXAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORPROMAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORPHENIRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLOROQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORAMPHENICOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CAPECITABINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BOCEPREVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BICALUTAMIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BASILIXIMAB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AZITHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATRASENTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ASENAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ARMODAFINIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMPRENAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMBRISENTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALOSETRON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALLOPURINOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALISKIREN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ACYCLOVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_590, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19</TD><TD>BC SATISFIED ASSERTION_598, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1424, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1423, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1388, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1426, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1387, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1422, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1421, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1386, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1420, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1440, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1399, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1439, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1385, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1417, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1416, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1398, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1414, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1182, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1415, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1412, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6</TD><TD>BC SATISFIED ASSERTION_1392, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1384, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1409, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1408, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1407, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1406, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1395, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1383, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6</TD><TD>BC SATISFIED ASSERTION_1391, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1403, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1382, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1400, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1418, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1437, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1436, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9</TD><TD>INHIBITION CONSTANT OF FLUOXETINE FOR CYP2C9 IS 0.005568, FLUOXETINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C9, MAXIMUM IN VIVO CONCENTRATION OF FLUOXETINE IS 5.5e 5 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_248, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1136, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_832, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1080, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_687, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_44, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_351, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_727, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_1001, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1022, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_349, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_718, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1094, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_910, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2B6</TD><TD>BC SATISFIED ASSERTION_1125, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_887, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1172, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_537, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_500, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_715, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1090, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_183, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_1117, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_685, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2B6</TD><TD>BC SATISFIED ASSERTION_538, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_868, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_984, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A1</TD><TD>BC SATISFIED ASSERTION_930, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_67, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_877, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_672, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_75, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_839, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_37, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_213, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_108, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_933, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_501, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_507, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1024, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_1226, </TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_488, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_334, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_192, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_473, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_964, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_803, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_199, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_261, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_668, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_130, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_751, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2B6</TD><TD>BC SATISFIED ASSERTION_124, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1181, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_203, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_1018, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1245, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1184, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_321, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_459, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_115, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_207, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_897, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_758, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_52, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_51, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_173, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_231, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1207, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_940, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_1118, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_946, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5</TD><TD>BC SATISFIED ASSERTION_610, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_16, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_662, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_870, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_861, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_71, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1165, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_855, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1086, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_820, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_182, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_208, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_274, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_734, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_757, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2B6</TD><TD>BC SATISFIED ASSERTION_398, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_55, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_896, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_612, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_484, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_755, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_31, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_523, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1092, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_872, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_697, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_784, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_387, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1364, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1303, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_63, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_211, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_251, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_881, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_511, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1656, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1639, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_595, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_454, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1141, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1456, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1642, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1350, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1380, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1315, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1093, </TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1381, </TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1302, </TD></TR><BR>
<TR><TD>Z</TD><TD>TIGECYCLINE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1328, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1330, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE INHIBITS CYP2B6</TD><TD>BC SATISFIED ASSERTION_1317, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1314, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1455, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1028, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1205, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1313, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_989, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1379, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELAPREVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1343, </TD></TR><BR>
<TR><TD>Z</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1327, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_430, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_65, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_320, </TD></TR><BR>
<TR><TD>Z</TD><TD>RIFAMPIN INHIBITS OATP1B3</TD><TD>BC SATISFIED ASSERTION_1500, </TD></TR><BR>
<TR><TD>Z</TD><TD>RIFAMPIN INHIBITS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1483, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1454, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1151, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1152, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_369, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1363, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1378, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1453, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1650, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1646, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1032, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1377, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1311, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRASUGREL INHIBITS CYP2B6</TD><TD>BC SATISFIED ASSERTION_1318, </TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1342, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1301, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1362, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1376, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1223, </TD></TR><BR>
<TR><TD>Z</TD><TD>OXANDROLONE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1321, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1333, </TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLOXACIN INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1310, </TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1361, </TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1341, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1657, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1640, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1195, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_688, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_287, </TD></TR><BR>
<TR><TD>Z</TD><TD>MICONAZOLE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1320, </TD></TR><BR>
<TR><TD>Z</TD><TD>METRONIDAZOLE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1326, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHOXSALEN INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1300, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1375, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1655, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1649, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1360, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1458, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1637, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_630, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1338, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1452, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1636, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1158, </TD></TR><BR>
<TR><TD>Z</TD><TD>ISONIAZID INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1359, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_486, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1349, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1374, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_296, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1373, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDRALAZINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1372, </TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL INHIBITS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1482, </TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL INHIBITS CYP2C8</TD><TD>BC SATISFIED ASSERTION_1319, </TD></TR><BR>
<TR><TD>Z</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1348, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1358, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_221, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1325, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1357, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_177, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1332, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_201, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_29, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1329, </TD></TR><BR>
<TR><TD>Z</TD><TD>FELBAMATE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1337, </TD></TR><BR>
<TR><TD>Z</TD><TD>FEBUXOSTAT INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1370, </TD></TR><BR>
<TR><TD>Z</TD><TD>FAMOTIDINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1309, </TD></TR><BR>
<TR><TD>Z</TD><TD>ETRAVIRINE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1324, </TD></TR><BR>
<TR><TD>Z</TD><TD>ETRAVIRINE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1336, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1331, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1459, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1643, </TD></TR><BR>
<TR><TD>Z</TD><TD>ELTROMBOPAG INHIBITS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1481, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_764, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1450, </TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1645, </TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1641, </TD></TR><BR>
<TR><TD>Z</TD><TD>DISULFIRAM INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1308, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1369, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1449, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1644, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1368, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1367, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1448, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE INHIBITS OATP1B3</TD><TD>BC SATISFIED ASSERTION_1499, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE INHIBITS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1480, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1356, </TD></TR><BR>
<TR><TD>Z</TD><TD>CRIZOTINIB INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1347, </TD></TR><BR>
<TR><TD>Z</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1323, </TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1447, </TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1638, </TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1340, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOPIDOGREL INHIBITS CYP2B6</TD><TD>BC SATISFIED ASSERTION_1316, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOBAZAM INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1365, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1446, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_714, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_713, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1346, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_313, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1057, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1658, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1654, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1355, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1366, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1335, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1307, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_388, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAPECITABINE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1322, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1306, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_854, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>BOCEPREVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1339, </TD></TR><BR>
<TR><TD>Z</TD><TD>BICALUTAMIDE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1353, </TD></TR><BR>
<TR><TD>Z</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1457, </TD></TR><BR>
<TR><TD>Z</TD><TD>AZITHROMYCIN INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1653, </TD></TR><BR>
<TR><TD>Z</TD><TD>AZITHROMYCIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1648, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_241, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_242, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARMODAFINIL INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1334, </TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1345, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMPRENAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1344, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1443, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1651, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_695, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_404, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_403, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1250, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1351, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALLOPURINOL INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1305, </TD></TR><BR>
<TR><TD>Z</TD><TD>ACYCLOVIR INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1304, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>AMIODARONE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>AMIODARONE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>AMIODARONE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>AMIODARONE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>AMIODARONE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>AZITHROMYCIN INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>AZITHROMYCIN INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>AZITHROMYCIN INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>AZITHROMYCIN INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>AZITHROMYCIN INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOPIDOGREL INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>CLOPIDOGREL INHIBITS CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOPIDOGREL INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>CLOPIDOGREL INHIBITS CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOPIDOGREL INHIBITS METABOLIC CLEARANCE OF PROPOFOL HYDROXYLATION VIA CYP2B6</TD><TD>CLOPIDOGREL INHIBITS CYP2B6, PROPOFOL HYDROXYLATION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOPIDOGREL INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN N DEMETHYLATION VIA CYP2B6</TD><TD>CLOPIDOGREL INHIBITS CYP2B6, S MEPHENYTOIN N DEMETHYLATION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>CONIVAPTAN INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>CONIVAPTAN INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>CONIVAPTAN INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>CONIVAPTAN INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>CONIVAPTAN INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN ACID VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, SIMVASTATIN ACID IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, ROSUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF RIFAMPIN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, RIFAMPIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF PRAVASTATIN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, PRAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF PITAVASTATIN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, PITAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF IRINOTECAN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, IRINOTECAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, FLUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF EZETIMIBE VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, EZETIMIBE IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ATRASENTAN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, ATRASENTAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, ATORVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B3</TD><TD>CYCLOSPORINE INHIBITS OATP1B3, ROSUVASTATIN IS SUBSTRATE OF OATP1B3, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF PITAVASTATIN VIA OATP1B3</TD><TD>CYCLOSPORINE INHIBITS OATP1B3, PITAVASTATIN IS SUBSTRATE OF OATP1B3, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA OATP1B3</TD><TD>CYCLOSPORINE INHIBITS OATP1B3, ATORVASTATIN IS SUBSTRATE OF OATP1B3, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>DILTIAZEM INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>DILTIAZEM INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>DILTIAZEM INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>DILTIAZEM INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>DILTIAZEM INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>DRONEDARONE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>DRONEDARONE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>DRONEDARONE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>DRONEDARONE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>DRONEDARONE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN ACID VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, SIMVASTATIN ACID IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, ROSUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF RIFAMPIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, RIFAMPIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF PRAVASTATIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, PRAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF PITAVASTATIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, PITAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF IRINOTECAN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, IRINOTECAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, FLUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF EZETIMIBE VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, EZETIMIBE IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF ATRASENTAN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, ATRASENTAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, ATORVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>ERYTHROMYCIN INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>ERYTHROMYCIN INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>ERYTHROMYCIN INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>ERYTHROMYCIN INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>ERYTHROMYCIN INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF AMODIAQUINE N DEETHYLATION VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, AMODIAQUINE N DEETHYLATION IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN ACID VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, SIMVASTATIN ACID IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, ROSUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF RIFAMPIN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, RIFAMPIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF PRAVASTATIN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, PRAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF PITAVASTATIN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, PITAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF IRINOTECAN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, IRINOTECAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, FLUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF EZETIMIBE VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, EZETIMIBE IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF ATRASENTAN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, ATRASENTAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, ATORVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>ITRACONAZOLE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>ITRACONAZOLE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>ITRACONAZOLE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>ITRACONAZOLE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>ITRACONAZOLE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>KETOCONAZOLE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>KETOCONAZOLE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>KETOCONAZOLE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>KETOCONAZOLE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>KETOCONAZOLE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>LAPATINIB INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>LAPATINIB INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>LAPATINIB INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>LAPATINIB INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>LAPATINIB INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PRASUGREL INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>PRASUGREL INHIBITS CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PRASUGREL INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>PRASUGREL INHIBITS CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PRASUGREL INHIBITS METABOLIC CLEARANCE OF PROPOFOL HYDROXYLATION VIA CYP2B6</TD><TD>PRASUGREL INHIBITS CYP2B6, PROPOFOL HYDROXYLATION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PRASUGREL INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN N DEMETHYLATION VIA CYP2B6</TD><TD>PRASUGREL INHIBITS CYP2B6, S MEPHENYTOIN N DEMETHYLATION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>QUINIDINE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>QUINIDINE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>QUINIDINE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>QUINIDINE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>QUINIDINE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN ACID VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, SIMVASTATIN ACID IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, ROSUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF PRAVASTATIN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, PRAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF PITAVASTATIN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, PITAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF IRINOTECAN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, IRINOTECAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, FLUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF EZETIMIBE VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, EZETIMIBE IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF ATRASENTAN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, ATRASENTAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, ATORVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B3</TD><TD>RIFAMPIN INHIBITS OATP1B3, ROSUVASTATIN IS SUBSTRATE OF OATP1B3, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF PITAVASTATIN VIA OATP1B3</TD><TD>RIFAMPIN INHIBITS OATP1B3, PITAVASTATIN IS SUBSTRATE OF OATP1B3, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA OATP1B3</TD><TD>RIFAMPIN INHIBITS OATP1B3, ATORVASTATIN IS SUBSTRATE OF OATP1B3, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>TICLOPIDINE INHIBITS CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>TICLOPIDINE INHIBITS CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF PROPOFOL HYDROXYLATION VIA CYP2B6</TD><TD>TICLOPIDINE INHIBITS CYP2B6, PROPOFOL HYDROXYLATION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN N DEMETHYLATION VIA CYP2B6</TD><TD>TICLOPIDINE INHIBITS CYP2B6, S MEPHENYTOIN N DEMETHYLATION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>VORICONAZOLE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>VORICONAZOLE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>VORICONAZOLE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>VORICONAZOLE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>VORICONAZOLE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DIGOXIN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ARMODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ARMODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ARMODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ARMODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOBAZAM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FEBUXOSTAT INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDRALAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHADONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAPECITABINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAPECITABINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CELECOXIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>CELECOXIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOBAZAM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOBAZAM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOBAZAM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOPIDOGREL INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF BUPROPION</TD><TD>CLOPIDOGREL INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOPIDOGREL INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF EFAVIRENZ</TD><TD>CLOPIDOGREL INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ETRAVIRINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ETRAVIRINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ETRAVIRINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ETRAVIRINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ETRAVIRINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ETRAVIRINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FEBUXOSTAT INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FEBUXOSTAT INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FEBUXOSTAT INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FELBAMATE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FELBAMATE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FELBAMATE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FELBAMATE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVASTATIN INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDRALAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDRALAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDRALAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHADONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHADONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHADONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METRONIDAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METRONIDAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OXANDROLONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OXANDROLONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PRASUGREL INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF BUPROPION</TD><TD>PRASUGREL INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PRASUGREL INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF EFAVIRENZ</TD><TD>PRASUGREL INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF BUPROPION</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF EFAVIRENZ</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TIGECYCLINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TIGECYCLINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF VORICONAZOLE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUVASTATIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF ZAFIRLUKAST IS 0.04</TD><TD>BC SATISFIED ASSERTION_1233, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF VORICONAZOLE IS 0.2</TD><TD>BC SATISFIED ASSERTION_482, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF VALPROATE IS 0.5</TD><TD>BC SATISFIED ASSERTION_889, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TRIMETHOPRIM IS 0.2</TD><TD>BC SATISFIED ASSERTION_197, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TOPIRAMATE IS 0.025</TD><TD>BC SATISFIED ASSERTION_477, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TOLBUTAMIDE IS 0.25</TD><TD>BC SATISFIED ASSERTION_983, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF THEOPHYLLINE IS 0.84</TD><TD>BC SATISFIED ASSERTION_794, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF RANOLAZINE IS 1.0</TD><TD>BC SATISFIED ASSERTION_185, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PROPOXYPHENE IS 0.065</TD><TD>BC SATISFIED ASSERTION_1033, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PROMETHAZINE IS 0.0125</TD><TD>BC SATISFIED ASSERTION_998, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PANTOPRAZOLE IS 0.02</TD><TD>BC SATISFIED ASSERTION_622, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF NICARDIPINE IS 0.06</TD><TD>BC SATISFIED ASSERTION_754, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF MIDODRINE IS 0.03</TD><TD>BC SATISFIED ASSERTION_23, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF METRONIDAZOLE IS 0.75</TD><TD>BC SATISFIED ASSERTION_429, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF LEFLUNOMIDE IS 0.01</TD><TD>BC SATISFIED ASSERTION_1208, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF LANSOPRAZOLE IS 0.015</TD><TD>BC SATISFIED ASSERTION_1060, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF FLUVASTATIN IS 0.02</TD><TD>BC SATISFIED ASSERTION_935, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF CELECOXIB IS 0.2</TD><TD>BC SATISFIED ASSERTION_589, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF ATORVASTATIN IS 0.01</TD><TD>BC SATISFIED ASSERTION_368, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF ZAFIRLUKAST IS 0.04</TD><TD>BC SATISFIED ASSERTION_512, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF VORICONAZOLE IS 0.6</TD><TD>BC SATISFIED ASSERTION_599, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF VALPROATE IS 4.2</TD><TD>BC SATISFIED ASSERTION_317, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TRIMETHOPRIM IS 0.2</TD><TD>BC SATISFIED ASSERTION_214, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TOPIRAMATE IS 0.4</TD><TD>BC SATISFIED ASSERTION_1131, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TOLBUTAMIDE IS 3.0</TD><TD>BC SATISFIED ASSERTION_4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF THEOPHYLLINE IS 1.05</TD><TD>BC SATISFIED ASSERTION_647, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF RANOLAZINE IS 2.0</TD><TD>BC SATISFIED ASSERTION_505, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PROPOXYPHENE IS 0.6</TD><TD>BC SATISFIED ASSERTION_307, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PROMETHAZINE IS 0.15</TD><TD>BC SATISFIED ASSERTION_1150, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PANTOPRAZOLE IS 0.24</TD><TD>BC SATISFIED ASSERTION_738, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF NICARDIPINE IS 0.12</TD><TD>BC SATISFIED ASSERTION_135, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF MIDODRINE IS 0.04</TD><TD>BC SATISFIED ASSERTION_186, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF METRONIDAZOLE IS 4.0</TD><TD>BC SATISFIED ASSERTION_164, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF LEFLUNOMIDE IS 0.2</TD><TD>BC SATISFIED ASSERTION_924, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF LANSOPRAZOLE IS 0.18</TD><TD>BC SATISFIED ASSERTION_1008, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF FLUVASTATIN IS 0.8</TD><TD>BC SATISFIED ASSERTION_25, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF CELECOXIB IS 0.8</TD><TD>BC SATISFIED ASSERTION_967, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF ATORVASTATIN IS 0.08</TD><TD>BC SATISFIED ASSERTION_1089, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ZOSUQUIDAR FOR P GLYCOPROTEIN IS 1.529e 5</TD><TD>BC SATISFIED ASSERTION_1628, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF VERAPAMIL FOR P GLYCOPROTEIN IS 0.003637</TD><TD>BC SATISFIED ASSERTION_1633, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF VERAPAMIL FOR CYP0.004546A5 IS 0.004546</TD><TD>BC SATISFIED ASSERTION_1576, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF VERAPAMIL FOR CYP0.004546A4 IS 0.004546</TD><TD>BC SATISFIED ASSERTION_1572, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF VALSPODAR FOR P GLYCOPROTEIN IS 1.336e 4</TD><TD>BC SATISFIED ASSERTION_1632, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TRYPTAMINE FOR CYP2A6 IS 0.001643</TD><TD>BC SATISFIED ASSERTION_1518, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TROLEANDOMYCIN FOR CYP2.198e 4A5 IS 2.198e 4</TD><TD>BC SATISFIED ASSERTION_1575, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TROLEANDOMYCIN FOR CYP2.198e 4A4 IS 2.198e 4</TD><TD>BC SATISFIED ASSERTION_1571, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TRIMETHOPRIM FOR CYP2C8 IS 0.00929</TD><TD>BC SATISFIED ASSERTION_1541, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TRANYLCYPROMINE FOR CYP2A6 IS 2.664e 6</TD><TD>BC SATISFIED ASSERTION_1515, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TICLOPIDINE FOR CYP2C19 IS 3.165e 4</TD><TD>BC SATISFIED ASSERTION_1555, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TICLOPIDINE FOR CYP2B6 IS 5.276e 5</TD><TD>BC SATISFIED ASSERTION_1532, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF THIOTEPA FOR CYP2B6 IS 9.082e 4</TD><TD>BC SATISFIED ASSERTION_1530, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TACROLIMUS FOR P GLYCOPROTEIN IS 5.95e 4</TD><TD>BC SATISFIED ASSERTION_1631, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF SULPHAPHENAZOLE FOR CYP2C9 IS 4.087e 4</TD><TD>BC SATISFIED ASSERTION_1549, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF SERTRALINE FOR CYP2B6 IS 9.799e 4</TD><TD>BC SATISFIED ASSERTION_1528, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ROSIGLITAZONE FOR CYP2C8 IS 0.002002</TD><TD>BC SATISFIED ASSERTION_1543, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF RESERPINE FOR P GLYCOPROTEIN IS 8.522e 4</TD><TD>BC SATISFIED ASSERTION_1635, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF QUINIDINE FOR P GLYCOPROTEIN IS 7.137e 4</TD><TD>BC SATISFIED ASSERTION_1630, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF QUINIDINE FOR CYP2D6 IS 8.759e 5</TD><TD>BC SATISFIED ASSERTION_1558, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF QUERCETIN FOR CYP2C8 IS 0.001871</TD><TD>BC SATISFIED ASSERTION_1540, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PIOGLITAZONE FOR CYP2C8 IS 6.059e 4</TD><TD>BC SATISFIED ASSERTION_1544, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PILOCARPINE FOR CYP2A6 IS 8.33e 4</TD><TD>BC SATISFIED ASSERTION_1517, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PHENCYCLIDINE FOR CYP2B6 IS 0.002434</TD><TD>BC SATISFIED ASSERTION_1529, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF NOOTKATONE FOR CYP2C19 IS 1.092e 4</TD><TD>BC SATISFIED ASSERTION_1556, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF NELFINAVIR FOR P GLYCOPROTEIN IS 7.949e 4</TD><TD>BC SATISFIED ASSERTION_1629, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF MONTELUKAST FOR CYP2C8 IS 6.448e 4</TD><TD>BC SATISFIED ASSERTION_1539, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF METHOXSALEN FOR CYP2A6 IS 2.162e 6</TD><TD>BC SATISFIED ASSERTION_1516, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR P GLYCOPROTEIN IS 0.002817</TD><TD>BC SATISFIED ASSERTION_1627, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR CYP1.966e 6A5 IS 1.966e 6</TD><TD>BC SATISFIED ASSERTION_1573, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ITRACONAZOLE FOR CYP1.905e 4A5 IS 1.905e 4</TD><TD>BC SATISFIED ASSERTION_1574, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF GEMFIBROZIL FOR CYP2C8 IS 0.01727</TD><TD>BC SATISFIED ASSERTION_1542, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FURAFYLLINE FOR CYP1A2 IS 1.562e 4</TD><TD>BC SATISFIED ASSERTION_1509, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUVOXAMINE FOR CYP2C9 IS 0.002037</TD><TD>BC SATISFIED ASSERTION_1551, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUOXETINE FOR CYP2C9 IS 0.005568</TD><TD>BC SATISFIED ASSERTION_1552, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUCONAZOLE FOR CYP2C9 IS 0.002144</TD><TD>BC SATISFIED ASSERTION_1550, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ELACRIDAR FOR P GLYCOPROTEIN IS 2.255e 4</TD><TD>BC SATISFIED ASSERTION_1634, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF DIETHYLDITHIOCARBAMATE FOR CYP2E1 IS 0.00214</TD><TD>BC SATISFIED ASSERTION_1560, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CYCLOSPORINE FOR P GLYCOPROTEIN IS 6.013e 4</TD><TD>BC SATISFIED ASSERTION_1626, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOPIDOGREL FOR CYP2B6 IS 1.609e 4</TD><TD>BC SATISFIED ASSERTION_1531, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ALPHA NAPHTHOFLAVONE FOR CYP1A2 IS 2.723e 5</TD><TD>BC SATISFIED ASSERTION_1510, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CYP2B6 ISOPROPENYL CYP2B6 METHYL ADAMANTANE FOR CYP2B6 IS 0.001009</TD><TD>BC SATISFIED ASSERTION_1527, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS SUBSTRATE OF CYP2C19</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS SUBSTRATE OF CYP2C9</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS SUBSTRATE OF CYP2D6</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS SUBSTRATE OF CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS SUBSTRATE OF CYP2E1</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP2E1 DIMETHYLURIC ACID VIA CYP2E1, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS SUBSTRATE OF CYP3A4</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE IS SUBSTRATE OF CYP3A4</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESIPRAMINE IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALOSETRON IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION IS SUBSTRATE OF CYP2B6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DARIFENACIN IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DASATINIB IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ IS SUBSTRATE OF CYP2B6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>EVEROLIMUS IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUTICASONE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>LURASIDONE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MARAVIROC IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MELATONIN IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEBIVOLOL IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RAMELTEON IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>SILDENAFIL IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICAGRELOR IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLVAPTAN IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZOLPIDEM IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_591, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZOLPIDEM IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_592, ITRACONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1040, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZALEPLON IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_719, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_640, </TD></TR><BR>
<TR><TD>Z</TD><TD>WARFARIN IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1396, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_298, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_547, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_383, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_546, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1610, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRAZODONE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_654, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1479, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1478, </TD></TR><BR>
<TR><TD>Z</TD><TD>TIZANIDINE IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1390, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_895, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1579, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1389, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1611, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_796, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_957, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_580, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1169, </TD></TR><BR>
<TR><TD>Z</TD><TD>TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1477, </TD></TR><BR>
<TR><TD>Z</TD><TD>TACROLIMUS IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1435, </TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1581, </TD></TR><BR>
<TR><TD>Z</TD><TD>SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1476, </TD></TR><BR>
<TR><TD>Z</TD><TD>SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1475, </TD></TR><BR>
<TR><TD>Z</TD><TD>SIROLIMUS IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1434, </TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN ACID IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1491, </TD></TR><BR>
<TR><TD>Z</TD><TD>SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1474, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS SUBSTRATE OF OATP1B3</TD><TD>BC SATISFIED ASSERTION_1502, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1490, </TD></TR><BR>
<TR><TD>Z</TD><TD>RIFAMPIN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1495, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1473, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1188, PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RABEPRAZOLE IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_1129, </TD></TR><BR>
<TR><TD>Z</TD><TD>RABEPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1228, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1614, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1433, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1112, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPOFOL HYDROXYLATION IS SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1586, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1493, </TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1472, </TD></TR><BR>
<TR><TD>Z</TD><TD>PITAVASTATIN IS SUBSTRATE OF OATP1B3</TD><TD>BC SATISFIED ASSERTION_1503, </TD></TR><BR>
<TR><TD>Z</TD><TD>PITAVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1492, </TD></TR><BR>
<TR><TD>Z</TD><TD>PIMOZIDE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1432, </TD></TR><BR>
<TR><TD>Z</TD><TD>PIMOZIDE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1442, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1595, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1397, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1002, </TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_533, </TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_254, </TD></TR><BR>
<TR><TD>Z</TD><TD>PACLITAXEL IS SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1394, </TD></TR><BR>
<TR><TD>Z</TD><TD>P NITROPHENOL 3 HYDROXYLATION IS SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1603, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1597, </TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1471, </TD></TR><BR>
<TR><TD>Z</TD><TD>NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1612, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_152, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_1030, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1029, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1143, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_302, </TD></TR><BR>
<TR><TD>Z</TD><TD>MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1470, </TD></TR><BR>
<TR><TD>Z</TD><TD>LOVASTATIN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_155, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAURIC ACID 11 HYDROXYLATION IS SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1604, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1469, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_890, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1206, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_838, </TD></TR><BR>
<TR><TD>Z</TD><TD>IRINOTECAN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1498, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1468, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_780, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1488, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_712, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_59, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_58, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1594, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_802, </TD></TR><BR>
<TR><TD>Z</TD><TD>FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1467, </TD></TR><BR>
<TR><TD>Z</TD><TD>EZETIMIBE IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1487, </TD></TR><BR>
<TR><TD>Z</TD><TD>EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1466, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_181, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_465, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1608, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_127, PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_700, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1429, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIGOXIN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1465, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1609, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_265, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1601, </TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1464, </TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1463, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1428, </TD></TR><BR>
<TR><TD>Z</TD><TD>COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1462, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_367, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_262, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_922, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_966, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_856, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1019, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_194, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_239, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1580, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATRASENTAN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1484, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS SUBSTRATE OF OATP1B3</TD><TD>BC SATISFIED ASSERTION_1501, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1485, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_48, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_552, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_632, </TD></TR><BR>
<TR><TD>Z</TD><TD>ANILINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1605, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMODIAQUINE N DEETHYLATION IS SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1589, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1461, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_97, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1460, </TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN N DEMETHYLATION IS SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1587, </TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1401, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_89, </TD></TR><BR>
<TR><TD>Z</TD><TD>7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1578, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM PERMANENTLY DEACTIVATES CATALYTIC FUNCTION OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_259, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE SULPHOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE METHYL HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THREOHYDROBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE 5 SULFOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TESTOSTERONE 6B HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TERIFLUNOMIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TERFENADINE C HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TAXOL 6 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE 1 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE PARA HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>REDUCED HALOPERIDOL IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE SULFOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROPOFOL HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENACETIN O DEETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>P NITROPHENOL 3 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE 5 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORPROPOXYPHENE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLUOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NIFEDIPINE OXIDATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NICOTINE C OXIDATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL SULFONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM 1 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LAURIC ACID 11 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXY HYDROCINNAMIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROCINNAMIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLURBIPROFEN 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE O DEALKYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROHYDROBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ HYDROXYLASE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DICLOFENAC 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN O DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESMETHYLCLOZAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESGLYMIDODRINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESACETYLDILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEHYDRO ARIPIPRAZOLE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>COUMARIN 7 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORZOXAZONE 6 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE 3 N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BUFURALOL 1 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BENZISOTHIAZOLE SULPHOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BENZISOTHIAZOLE SULPHONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ANILINE 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMODIAQUINE N DEETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPHA NAPHTHOFLAVONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPHA HYDROXYALPRAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S ZOPICLONE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S WARFARIN 7 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S METHYL DIHYDROZIPRASIDONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S N DESMETHYLZOPICLONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>O DESMETHYLVENLAFAXINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLVENLAFAXINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLTAMOXIFEN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLSERTRALINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLATOMOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYLDILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYLDESACETYL DILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYL_ERYTHROMYCIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>M CHLOROPHENYLPIPERAZINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>9 HYDROXYRISPERIDONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXYPERPHENAZINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXYCLOZAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXY QUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXY N DESALKYL QUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 ETHOXYRESORUFIN O DEETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME HYDROXYMETHYL SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME HYDROXY SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME EXOMETHYLENE SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME EXOMETHYLENE LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME BETA HYDROXY LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6BETA HYDROXYTESTOSTERONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYTRIAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYTAMOXIFIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYMIDAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYDEBRISOQUINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYATOMOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYALPRAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>3ALPHA HYDROXYPRAVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>3 METHYLXANTHINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>2 ISOPROPENYL 2 METHYL ADAMANTANE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1PRIME HYDROXYMIDAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>14 HYDROXYCLARITHROMYCIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>10 N GLUCURONIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1 METHYLXANTHINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1 METHYLURIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1,3 DIMETHYLURIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDODRINE IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LEFLUNOMIDE IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS ANCESTOR OF 3 METHYLXANTHINE</TD><TD>THEOPHYLLINE HAS METABOLITE CYP1A2 METHYLXANTHINE VIA CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION IS ANCESTOR OF HYDROXYBUPROPION</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION VIA CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS ANCESTOR OF N DESMETHYLATOMOXETINE</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE VIA CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS ANCESTOR OF N DESMETHYLROSUVASTATIN</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN VIA CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS ANCESTOR OF 4 HYDROXYATOMOXETINE</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE VIA CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS ANCESTOR OF 9 HYDROXYRISPERIDONE</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE IS ANCESTOR OF O DESMETHYLVENLAFAXINE</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE VIA CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS ANCESTOR OF 1,3 DIMETHYLURIC ACID</TD><TD>THEOPHYLLINE HAS METABOLITE 1,CYP3A4 DIMETHYLURIC ACID VIA CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE IS ANCESTOR OF N DESMETHYLVENLAFAXINE</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE VIA CYP3A4, </TD></TR><BR>
<TR><TD>(BC-SATISFIED 'ASSERTION_950)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_934)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_929)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_928)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_914)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_91)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_909)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_893)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_822)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_821)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_800)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_769)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_753)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_752)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_740)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_736)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_728)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_720)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_708)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_703)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_70)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_689)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_686)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_619)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_616)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_615)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_608)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_602)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_579)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_571)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_568)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_567)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_562)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_559)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_557)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_543)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_532)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_503)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_493)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_472)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_469)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_45)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_443)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_440)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_434)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_425)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_409)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_396)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_354)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_344)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_33)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_314)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_30)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_295)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_252)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_240)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_206)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_176)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_138)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1298)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1297)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1296)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1295)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1294)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1292)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1290)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_129)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1289)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1288)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1287)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1286)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1285)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1284)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1281)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1279)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1278)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1277)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1273)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1267)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1266)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1243)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1217)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1215)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1212)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1197)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1171)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1164)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_116)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1157)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1155)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1153)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1107)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1106)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_110)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1087)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1078)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_107)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1067)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1055)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1053)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1044)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_103)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1007)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1003)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_614)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_900)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_982)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_205)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_69)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_853)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_106)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1069)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_539)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_681)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_760)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1128)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1064)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_990)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_285)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1061)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_141)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1261)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_891)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_462)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1059)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_642)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_140)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_10)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_279)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_450)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_269)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_634)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_32)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1039)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_515)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1041)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1214)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_729)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_15)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_972)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1037)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_644)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_158)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_238)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_919)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_556)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_962)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_598)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1424)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1423)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1388)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1426)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1387)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1422)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1421)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1386)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1420)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1440)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1399)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1439)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1418)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1385)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1417)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1416)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1398)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1414)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1182)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1415)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1412)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1392)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1384)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1409)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1437)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1436)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1408)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1407)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1406)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1395)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1383)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1391)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1403)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1382)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1400)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_816)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1013)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1122)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1047)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_219)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1233)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_482)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_889)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_197)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_477)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_983)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_794)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_185)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1033)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_998)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_622)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_754)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_23)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_429)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1208)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1060)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_935)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_589)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_368)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_512)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_599)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_317)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_214)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1131)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_4)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_647)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_505)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_307)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1150)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_738)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_135)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_186)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_164)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_924)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1008)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_25)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_967)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1089)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_813)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_126)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_275)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_541)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_466)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1219)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_655)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1017)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_104)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_806)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1023)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_514)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_921)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_788)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_624)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_423)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_224)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_312)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_880)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1628)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1633)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1576)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1572)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1632)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1518)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1575)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1571)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1541)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1515)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1555)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1532)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1530)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1631)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1549)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1528)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1543)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1635)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1630)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1558)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1540)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1544)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1517)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1529)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1556)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1629)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1539)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1516)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1627)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1573)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1574)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1542)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1509)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1551)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1552)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1550)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1634)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1560)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1626)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1531)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1510)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1527)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_694)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_912)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1025)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_666)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_495)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1091)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_151)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_628)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_290)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_66)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_846)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_348)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_762)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_678)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_581)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_674)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_894)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_420)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_467)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1220)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_664)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1162)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_402)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_8)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1063)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_637)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_631)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_259)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_591)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_592)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1040)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_719)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_640)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1396)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_298)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_547)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_383)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_546)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1610)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_654)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1479)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1478)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1390)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_895)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1579)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1389)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1611)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_796)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_957)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_580)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1169)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1477)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1435)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1581)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1476)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1475)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1434)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1491)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1474)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1502)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1490)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1495)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1473)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1188)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1129)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1228)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1614)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1433)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1112)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1586)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1493)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1472)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1503)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1492)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1432)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1442)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1595)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1397)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1002)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_533)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_254)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1394)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1603)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1597)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1471)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1612)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_152)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1030)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1029)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1143)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_302)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1470)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_155)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1604)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1469)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_890)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1206)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_838)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1498)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1468)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_780)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1488)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_712)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_59)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_58)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1594)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_802)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1467)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1487)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1466)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_181)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_465)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1608)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_127)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_700)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1429)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1465)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1609)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_265)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1601)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1464)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1463)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1428)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1462)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_367)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_262)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_922)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_966)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_856)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1019)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_194)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_239)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1580)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1484)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1501)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1485)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_48)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_552)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_632)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1605)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1589)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1461)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_97)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1460)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1587)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1401)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_89)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1578)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_980)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_931)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_411)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_268)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_809)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_810)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_40)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_650)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_786)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_879)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_882)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_17)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_528)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_907)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_358)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_944)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_878)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_14)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1076)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_958)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_665)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1623)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1622)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1514)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1569)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1535)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1511)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1525)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1523)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1621)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1545)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1521)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1537)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1625)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1557)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1534)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1538)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1513)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1522)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1554)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1619)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1533)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1512)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1563)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1562)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1536)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1507)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1547)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1548)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1546)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1624)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1559)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1616)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1524)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1565)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1508)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1520)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1591)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1588)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1577)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_692)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1583)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1606)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1584)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1600)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1582)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1602)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1585)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1596)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_590)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1364)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1303)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_63)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_211)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_251)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_881)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_511)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1656)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1639)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_595)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_454)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1141)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1456)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1642)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1350)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1380)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1315)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1093)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1381)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1302)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1328)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1330)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1317)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1314)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1455)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1028)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1205)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1313)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_989)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1379)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1343)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1327)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_430)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_65)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_320)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1500)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1483)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1454)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1151)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1152)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_369)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1363)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1378)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1453)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1650)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1646)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1032)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1377)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1311)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1318)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1342)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1301)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1362)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1376)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1223)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1321)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1333)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1310)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1361)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1341)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1657)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1640)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1195)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_688)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_287)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1320)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1326)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1300)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1375)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1655)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1649)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1360)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1458)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1637)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_630)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1338)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1452)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1636)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1158)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1359)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_486)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1349)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1374)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_296)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1373)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1372)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1482)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1319)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1348)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1358)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_221)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1325)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1357)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_177)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1332)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_201)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_29)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1329)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1337)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1370)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1309)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1324)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1336)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1331)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1459)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1643)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1481)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_764)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1450)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1645)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1641)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1308)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1369)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1449)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1644)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1368)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1367)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1448)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1499)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1480)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1356)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1347)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1323)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1447)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1638)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1340)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1316)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1365)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1446)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_714)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_713)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1346)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_313)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1057)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1658)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1654)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1355)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1366)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1335)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1307)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_388)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1322)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1306)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_854)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1339)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1353)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1457)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1653)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1648)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_241)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_242)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1334)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1345)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1344)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1443)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1651)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_695)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_404)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_403)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1250)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1351)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1305)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1304)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_947)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_617)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1116)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_731)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_191)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_735)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_492)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_797)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_395)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_635)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1203)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_722)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_220)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_308)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1140)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_414)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_18)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1210)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_652)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_766)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1095)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_427)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1204)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_705)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_497)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_12)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_992)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_263)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_38)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1000)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_196)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_871)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_85)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_417)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_544)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_570)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_826)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_179)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1109)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_585)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_3)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_706)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1110)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1234)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_46)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_535)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_260)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_833)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_746)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1176)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_113)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_945)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_248)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1136)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_832)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1080)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_687)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_44)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_351)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_727)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1001)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1022)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_349)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_718)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1094)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_910)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1125)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_887)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1172)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_537)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_500)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_715)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1090)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_183)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1117)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_685)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_538)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_868)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_984)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_930)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_67)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_877)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_672)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_75)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_839)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_37)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_213)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_108)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_933)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_501)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_507)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1024)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1226)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_488)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_334)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_192)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_473)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_964)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_803)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_199)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_261)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_668)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_130)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_751)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_124)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1181)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_203)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1018)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1245)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1184)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_321)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_459)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_115)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_207)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_897)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_758)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_52)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_51)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_173)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_231)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1207)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_940)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1118)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_946)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_610)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_16)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_662)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_870)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_861)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_71)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1165)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_855)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1086)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_820)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_182)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_208)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_274)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_734)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_757)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_398)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_55)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_896)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_612)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_484)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_755)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_31)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_523)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1092)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_872)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_697)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_784)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_387)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_508)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_28)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_175)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_739)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_996)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_304)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_244)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_487)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1186)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_264)</TD></TR>
<TR><TD>Z</TD><TD>ZIPRASIDONE HAS METABOLITE ZIPRASIDONE SULPHOXIDE</TD><TD>BC SATISFIED ASSERTION_947, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE HAS METABOLITE BENZISOTHIAZOLE SULPHOXIDE</TD><TD>BC SATISFIED ASSERTION_617, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE HAS METABOLITE BENZISOTHIAZOLE SULPHONE</TD><TD>BC SATISFIED ASSERTION_1116, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE HAS METABOLITE S METHYL DIHYDROZIPRASIDONE</TD><TD>BC SATISFIED ASSERTION_731, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE HAS METABOLITE VORICONAZOLE N OXIDE</TD><TD>BC SATISFIED ASSERTION_191, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE</TD><TD>BC SATISFIED ASSERTION_735, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE HAS METABOLITE N DESMETHYLVENLAFAXINE</TD><TD>BC SATISFIED ASSERTION_492, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRAZODONE HAS METABOLITE M CHLOROPHENYLPIPERAZINE</TD><TD>BC SATISFIED ASSERTION_797, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE HAS METABOLITE SULFORIDAZINE</TD><TD>BC SATISFIED ASSERTION_395, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE HAS METABOLITE MESORIDAZINE</TD><TD>BC SATISFIED ASSERTION_635, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE CAFFEINE</TD><TD>BC SATISFIED ASSERTION_1203, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 3 METHYLXANTHINE</TD><TD>BC SATISFIED ASSERTION_722, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 1 METHYLXANTHINE</TD><TD>BC SATISFIED ASSERTION_220, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE HAS METABOLITE 1,3 DIMETHYLURIC ACID</TD><TD>BC SATISFIED ASSERTION_308, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN HAS METABOLITE N DESMETHYLTAMOXIFEN</TD><TD>BC SATISFIED ASSERTION_1140, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN HAS METABOLITE 4 HYDROXYTAMOXIFIN</TD><TD>BC SATISFIED ASSERTION_414, </TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN HAS METABOLITE BETA HYDROXY SIMVASTATIN</TD><TD>BC SATISFIED ASSERTION_18, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE HAS METABOLITE N DESMETHYLSERTRALINE</TD><TD>BC SATISFIED ASSERTION_1210, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN HAS METABOLITE N DESMETHYLROSUVASTATIN</TD><TD>BC SATISFIED ASSERTION_652, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE</TD><TD>BC SATISFIED ASSERTION_766, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE N DESALKYLQUETIAPINE</TD><TD>BC SATISFIED ASSERTION_1095, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPOXYPHENE HAS METABOLITE NORPROPOXYPHENE</TD><TD>BC SATISFIED ASSERTION_427, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN HAS METABOLITE 3ALPHA HYDROXYPRAVASTATIN</TD><TD>BC SATISFIED ASSERTION_1204, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE HAS METABOLITE 7 HYDROXYPERPHENAZINE</TD><TD>BC SATISFIED ASSERTION_705, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL HAS METABOLITE MODAFINIL SULFONE</TD><TD>BC SATISFIED ASSERTION_497, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIDODRINE HAS METABOLITE DESGLYMIDODRINE</TD><TD>BC SATISFIED ASSERTION_12, </TD></TR><BR>
<TR><TD>Z</TD><TD>LOVASTATIN HAS METABOLITE BETA HYDROXY LOVASTATIN</TD><TD>BC SATISFIED ASSERTION_992, </TD></TR><BR>
<TR><TD>Z</TD><TD>LEFLUNOMIDE HAS METABOLITE TERIFLUNOMIDE</TD><TD>BC SATISFIED ASSERTION_263, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE HAS METABOLITE NORFLUOXETINE</TD><TD>BC SATISFIED ASSERTION_38, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE HAS METABOLITE S ZOPICLONE N OXIDE</TD><TD>BC SATISFIED ASSERTION_1000, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE HAS METABOLITE S N DESMETHYLZOPICLONE</TD><TD>BC SATISFIED ASSERTION_196, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM HAS METABOLITE S DIDEMETHYLCITALOPRAM</TD><TD>BC SATISFIED ASSERTION_871, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM HAS METABOLITE S DEMETHYLCITALOPRAM</TD><TD>BC SATISFIED ASSERTION_85, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN HAS METABOLITE 14 HYDROXYCLARITHROMYCIN</TD><TD>BC SATISFIED ASSERTION_417, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM HAS METABOLITE DIDEMETHYLCITALOPRAM</TD><TD>BC SATISFIED ASSERTION_544, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM HAS METABOLITE DEMETHYLCITALOPRAM</TD><TD>BC SATISFIED ASSERTION_570, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET HAS METABOLITE HYDROXY HYDROCINNAMIC ACID</TD><TD>BC SATISFIED ASSERTION_826, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET HAS METABOLITE HYDROCINNAMIC ACID</TD><TD>BC SATISFIED ASSERTION_179, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HAS METABOLITE THREOHYDROBUPROPION</TD><TD>BC SATISFIED ASSERTION_1109, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HAS METABOLITE HYDROXYBUPROPION</TD><TD>BC SATISFIED ASSERTION_585, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HAS METABOLITE ERYTHROHYDROBUPROPION</TD><TD>BC SATISFIED ASSERTION_3, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN HAS METABOLITE 6PRIME HYDROXYMETHYL SIMVASTATIN</TD><TD>BC SATISFIED ASSERTION_706, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN HAS METABOLITE 6PRIME HYDROXY SIMVASTATIN</TD><TD>BC SATISFIED ASSERTION_1110, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN HAS METABOLITE 6PRIME EXOMETHYLENE SIMVASTATIN</TD><TD>BC SATISFIED ASSERTION_1234, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN</TD><TD>BC SATISFIED ASSERTION_46, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN</TD><TD>BC SATISFIED ASSERTION_535, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE HAS METABOLITE N DESMETHYLATOMOXETINE</TD><TD>BC SATISFIED ASSERTION_260, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE HAS METABOLITE 4 HYDROXYATOMOXETINE</TD><TD>BC SATISFIED ASSERTION_833, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE HAS METABOLITE DEHYDRO ARIPIPRAZOLE</TD><TD>BC SATISFIED ASSERTION_746, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM HAS METABOLITE ALPHA HYDROXYALPRAZOLAM</TD><TD>BC SATISFIED ASSERTION_1176, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM HAS METABOLITE 4 HYDROXYALPRAZOLAM</TD><TD>BC SATISFIED ASSERTION_113, </TD></TR><BR>
<TR><TD>Z</TD><TD>1 METHYLXANTHINE HAS METABOLITE 1 METHYLURIC ACID</TD><TD>BC SATISFIED ASSERTION_945, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE METHYL HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1591, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAXOL 6 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1588, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENACETIN O DEETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1577, </TD></TR><BR>
<TR><TD>Z</TD><TD>PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_692, </TD></TR><BR>
<TR><TD>Z</TD><TD>NICOTINE C OXIDATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1583, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM 1 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1606, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ HYDROXYLASE IS AN IN VITRO PROBE SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1584, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN O DEMETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1600, </TD></TR><BR>
<TR><TD>Z</TD><TD>COUMARIN 7 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1582, </TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORZOXAZONE 6 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1602, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1585, </TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN 4 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1596, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1623, </TD></TR><BR>
<TR><TD>Z</TD><TD>VALSPODAR IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1622, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRYPTAMINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1514, </TD></TR><BR>
<TR><TD>Z</TD><TD>TROLEANDOMYCIN IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_1569, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRIMETHOPRIM IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1535, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRANYLCYPROMINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1511, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1525, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTEPA IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1523, </TD></TR><BR>
<TR><TD>Z</TD><TD>TACROLIMUS IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1621, </TD></TR><BR>
<TR><TD>Z</TD><TD>SULPHAPHENAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1545, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1521, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1537, </TD></TR><BR>
<TR><TD>Z</TD><TD>RESERPINE IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1625, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1557, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUERCETIN IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1534, </TD></TR><BR>
<TR><TD>Z</TD><TD>PIOGLITAZONE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1538, </TD></TR><BR>
<TR><TD>Z</TD><TD>PILOCARPINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1513, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENCYCLIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1522, </TD></TR><BR>
<TR><TD>Z</TD><TD>NOOTKATONE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1554, </TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1619, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1533, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHOXSALEN IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1512, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_1563, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1562, </TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1536, </TD></TR><BR>
<TR><TD>Z</TD><TD>FURAFYLLINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1507, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1547, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1548, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1546, </TD></TR><BR>
<TR><TD>Z</TD><TD>ELACRIDAR IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1624, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIETHYLDITHIOCARBAMATE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1559, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1616, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOPIDOGREL IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1524, </TD></TR><BR>
<TR><TD>Z</TD><TD>AZAMULIN IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1565, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPHA NAPHTHOFLAVONE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1508, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP2B6 ISOPROPENYL CYP2B6 METHYL ADAMANTANE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1520, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_980, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZALEPLON IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_931, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_411, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_268, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_809, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_810, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_40, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_650, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_786, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_879, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A1</TD><TD>BC SATISFIED ASSERTION_882, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_17, </TD></TR><BR>
<TR><TD>Z</TD><TD>ASENAPINE IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_528, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_907, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_358, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_944, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_878, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_14, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1076, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_958, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A1</TD><TD>BC SATISFIED ASSERTION_665, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ZALEPLON IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_694, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF VORICONAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_912, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF TRAZODONE IS HIGH</TD><TD>BC SATISFIED ASSERTION_1025, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ROSUVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_666, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF RISPERIDONE IS HIGH</TD><TD>BC SATISFIED ASSERTION_495, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF RABEPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_1091, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF PANTOPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_151, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF PALIPERIDONE IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_628, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF NICARDIPINE IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_290, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF MIRTAZAPINE IS MEDIUM HIGH</TD><TD>BC SATISFIED ASSERTION_66, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF MIDODRINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_846, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF LOVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_348, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF LANSOPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_762, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF INDOMETHACIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_678, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUVOXAMINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_581, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUVASTATIN IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_674, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUPHENAZINE IS LOW</TD><TD>BC SATISFIED ASSERTION_894, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUCONAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_420, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ESCITALOPRAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_467, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF DILTIAZEM IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_1220, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CLARITHROMYCIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_664, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CITALOPRAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_1162, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CHLORPROMAZINE IS LOW</TD><TD>BC SATISFIED ASSERTION_402, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ATORVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_8, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ATOMOXETINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_1063, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ARIPIPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_637, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ALPRAZOLAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_631, </TD></TR><BR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         '2-ISOPROPENYL-2-METHYL-ADAMANTANE 'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ALPHA-NAPHTHOFLAVONE 'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOPIDOGREL
         'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'CYCLOSPORINE 'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'DIETHYLDITHIOCARBAMATE 'CYP2E1)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'ELACRIDAR
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUCONAZOLE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUOXETINE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUVOXAMINE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FURAFYLLINE
         'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'GEMFIBROZIL
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ITRACONAZOLE 'CYP3A5)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'KETOCONAZOLE 'CYP3A5)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'KETOCONAZOLE 'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'METHOXSALEN
         'CYP2A6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'MONTELUKAST
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'NELFINAVIR
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'NOOTKATONE
         'CYP2C19)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PHENCYCLIDINE 'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'PILOCARPINE
         'CYP2A6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PIOGLITAZONE 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'QUERCETIN
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'QUINIDINE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'QUINIDINE
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'RESERPINE
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ROSIGLITAZONE 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'SERTRALINE
         'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'SULPHAPHENAZOLE 'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'TACROLIMUS
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'THIOTEPA
         'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'TICLOPIDINE
         'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'TICLOPIDINE
         'CYP2C19)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'TRANYLCYPROMINE 'CYP2A6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'TRIMETHOPRIM 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'TROLEANDOMYCIN 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'TROLEANDOMYCIN 'CYP3A5)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'TRYPTAMINE
         'CYP2A6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'VALSPODAR
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'VERAPAMIL
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'VERAPAMIL
         'CYP3A5)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'VERAPAMIL
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'ZOSUQUIDAR
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ZOLPIDEM IS 1.06e 4 AT DOSE 0.01</TD><TD>BC SATISFIED ASSERTION_813, ASSUMED EFFECTIVE DOSE OF ZOLPIDEM IS 0.01, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF VORICONAZOLE IS 4.66e 4 AT DOSE 0.6</TD><TD>BC SATISFIED ASSERTION_275, ASSUMED EFFECTIVE DOSE OF VORICONAZOLE IS 0.6, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF RANOLAZINE IS 2.6e 4 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_541, ASSUMED EFFECTIVE DOSE OF RANOLAZINE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF PERPHENAZINE IS 9.84e 7 AT DOSE 0.004</TD><TD>BC SATISFIED ASSERTION_466, ASSUMED EFFECTIVE DOSE OF PERPHENAZINE IS 0.004, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF PANTOPRAZOLE IS 2.5e 4 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1219, ASSUMED EFFECTIVE DOSE OF PANTOPRAZOLE IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF METRONIDAZOLE IS 0.004 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_655, ASSUMED EFFECTIVE DOSE OF METRONIDAZOLE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF LOVASTATIN IS 7.8e 6 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1017, ASSUMED EFFECTIVE DOSE OF LOVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF LANSOPRAZOLE IS 0.004 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_104, ASSUMED EFFECTIVE DOSE OF LANSOPRAZOLE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUVASTATIN IS 4.0.04e 4 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_806, ASSUMED EFFECTIVE DOSE OF FLUVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUOXETINE IS 5.5e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1023, ASSUMED EFFECTIVE DOSE OF FLUOXETINE IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUCONAZOLE IS 0.007 AT DOSE 0.4</TD><TD>BC SATISFIED ASSERTION_514, ASSUMED EFFECTIVE DOSE OF FLUCONAZOLE IS 0.4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CLOZAPINE IS 5.64e 4 AT DOSE 0.15</TD><TD>BC SATISFIED ASSERTION_921, ASSUMED EFFECTIVE DOSE OF CLOZAPINE IS 0.15, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CELECOXIB IS 7.05e 5 AT DOSE 0.2</TD><TD>BC SATISFIED ASSERTION_788, ASSUMED EFFECTIVE DOSE OF CELECOXIB IS 0.2, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF BUPROPION IS 1.44e 4 AT DOSE 0.15</TD><TD>BC SATISFIED ASSERTION_624, ASSUMED EFFECTIVE DOSE OF BUPROPION IS 0.15, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF BETA HYDROXY LOVASTATIN IS 1.19e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_423, ASSUMED EFFECTIVE DOSE OF BETA HYDROXY LOVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ASENAPINE IS 4.e 6 AT DOSE 0.005</TD><TD>BC SATISFIED ASSERTION_224, ASSUMED EFFECTIVE DOSE OF ASENAPINE IS 0.005, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ALPRAZOLAM IS 0.003.7e 5 AT DOSE 0.003</TD><TD>BC SATISFIED ASSERTION_312, ASSUMED EFFECTIVE DOSE OF ALPRAZOLAM IS 0.003, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF 7 HYDROXYPERPHENAZINE IS 5.09e 7 AT DOSE 0.004</TD><TD>BC SATISFIED ASSERTION_880, ASSUMED EFFECTIVE DOSE OF 7 HYDROXYPERPHENAZINE IS 0.004, </TD></TR><BR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ZOLPIDEM '0.01)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'VORICONAZOLE '0.6)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'RANOLAZINE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'PERPHENAZINE '0.004)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'PANTOPRAZOLE '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'METRONIDAZOLE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'LOVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'LANSOPRAZOLE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUOXETINE '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUCONAZOLE '0.4)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CLOZAPINE '0.15)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CELECOXIB '0.2)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'BUPROPION '0.15)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'BETA-HYDROXY-LOVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ASENAPINE '0.005)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ALPRAZOLAM '0.003)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 '7-HYDROXYPERPHENAZINE '0.004)</TD></TR>
<TR><TD>Z</TD><TD>ORAL DOSE FRACTION ABSORBED OF ROSUVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_1047, </TD></TR><BR>
<TR><TD>Z</TD><TD>ORAL DOSE FRACTION ABSORBED OF CLARITHROMYCIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_219, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_816, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY METABOLIC CLEARANCE ENZYME OF RISPERIDONE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1013, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY METABOLIC CLEARANCE ENZYME OF ALPRAZOLAM IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1122, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DESIPRAMINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DEXTROMETHORPHAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MIDAZOLAM IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF S MEPHENYTOIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ALOSETRON IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF APREPITANT IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF BUPROPION IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CAFFEINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CELECOXIB IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CONIVAPTAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DARIFENACIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DASATINIB IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DRONEDARONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DULOXETINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF EFAVIRENZ IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF EVEROLIMUS IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUTICASONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF INDINAVIR IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LANSOPRAZOLE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LURASIDONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MARAVIROC IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MELATONIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF NEBIVOLOL IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF OMEPRAZOLE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PERPHENAZINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF QUETIAPINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RAMELTEON IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SILDENAFIL IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SIROLIMUS IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TACRINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TICAGRELOR IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TIZANIDINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TOLVAPTAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TRIAZOLAM IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF VORICONAZOLE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF VORICONAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ZIPRASIDONE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_614, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ZALEPLON IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_900, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF VORICONAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_982, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF VENLAFAXINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_205, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF VALPROATE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_69, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TOPIRAMATE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_853, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF THREOHYDROBUPROPION IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_106, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF THEOPHYLLINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1069, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TAMOXIFEN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_539, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SIMVASTATIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_681, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS BILIARY_EXCRETION</TD><TD>BC SATISFIED ASSERTION_760, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RISPERIDONE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1128, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RANOLAZINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1064, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RABEPRAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_990, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF QUETIAPINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_285, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PERPHENAZINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1061, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PAROXETINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_141, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PANTOPRAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1261, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PALIPERIDONE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_891, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MOLINDONE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_462, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MODAFINIL IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1059, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LOVASTATIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_642, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LANSOPRAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_140, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF KETOCONAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_10, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF INDOMETHACIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_279, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF HYDROXYBUPROPION IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_450, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUVOXAMINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_269, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUVASTATIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_634, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUOXETINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_32, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUCONAZOLE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_1039, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DULOXETINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_515, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DILTIAZEM IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1041, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DESGLYMIDODRINE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_1214, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CLOZAPINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_729, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CITALOPRAM IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_15, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CINACALCET IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_972, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CELECOXIB IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1037, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ATORVASTATIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_644, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ATOMOXETINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_158, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ASENAPINE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_238, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ARIPIPRAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_919, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ALPRAZOLAM IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_556, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF 9 HYDROXYRISPERIDONE IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_962, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, ATOMOXETINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, ROSUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATOMOXETINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, ATOMOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP2E1</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2E1, THEOPHYLLINE IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, THEOPHYLLINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, VENLAFAXINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>N DESALKYLQUETIAPINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ARIPIPRAZOLE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PROPOFOL HYDROXYLATION VIA CYP2B6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2B6, PROPOFOL HYDROXYLATION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN N DEMETHYLATION VIA CYP2B6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2B6, S MEPHENYTOIN N DEMETHYLATION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF P NITROPHENOL CYP2E1 HYDROXYLATION VIA CYP2E1</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2E1, P NITROPHENOL 3 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LAURIC ACID 11 HYDROXYLATION VIA CYP2E1</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2E1, LAURIC ACID 11 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ANILINE 4 HYDROXYLATION VIA CYP2E1</TD><TD>ATAZANAVIR DOES NOT INHIBIT CYP2E1, ANILINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATOMOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ATOMOXETINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CELECOXIB DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CELECOXIB DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>CINACALCET DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CINACALCET DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>CINACALCET DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF P NITROPHENOL CYP2E1 HYDROXYLATION VIA CYP2E1</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2E1, P NITROPHENOL 3 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LAURIC ACID 11 HYDROXYLATION VIA CYP2E1</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2E1, LAURIC ACID 11 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ANILINE 4 HYDROXYLATION VIA CYP2E1</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2E1, ANILINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>DEHYDRO ARIPIPRAZOLE DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>DULOXETINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>DULOXETINE DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF P NITROPHENOL CYP2E1 HYDROXYLATION VIA CYP2E1</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2E1, P NITROPHENOL 3 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LAURIC ACID 11 HYDROXYLATION VIA CYP2E1</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2E1, LAURIC ACID 11 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ANILINE 4 HYDROXYLATION VIA CYP2E1</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2E1, ANILINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF P NITROPHENOL CYP2E1 HYDROXYLATION VIA CYP2E1</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2E1, P NITROPHENOL 3 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LAURIC ACID 11 HYDROXYLATION VIA CYP2E1</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2E1, LAURIC ACID 11 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ANILINE 4 HYDROXYLATION VIA CYP2E1</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP2E1, ANILINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESZOPICLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ESZOPICLONE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>INDINAVIR DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PROPOFOL HYDROXYLATION VIA CYP2B6</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2B6, PROPOFOL HYDROXYLATION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN N DEMETHYLATION VIA CYP2B6</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2B6, S MEPHENYTOIN N DEMETHYLATION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF P NITROPHENOL CYP2E1 HYDROXYLATION VIA CYP2E1</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2E1, P NITROPHENOL 3 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LAURIC ACID 11 HYDROXYLATION VIA CYP2E1</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2E1, LAURIC ACID 11 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ANILINE 4 HYDROXYLATION VIA CYP2E1</TD><TD>INDINAVIR DOES NOT INHIBIT CYP2E1, ANILINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF AMODIAQUINE N DEETHYLATION VIA CYP2C8</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C8, AMODIAQUINE N DEETHYLATION IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MONTELUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>MONTELUKAST DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>NEFAZODONE DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF AMODIAQUINE N DEETHYLATION VIA CYP2C8</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C8, AMODIAQUINE N DEETHYLATION IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF P NITROPHENOL CYP2E1 HYDROXYLATION VIA CYP2E1</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2E1, P NITROPHENOL 3 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LAURIC ACID 11 HYDROXYLATION VIA CYP2E1</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2E1, LAURIC ACID 11 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ANILINE 4 HYDROXYLATION VIA CYP2E1</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP2E1, ANILINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PALIPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>PALIPERIDONE DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUETIAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>QUETIAPINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PROPOFOL HYDROXYLATION VIA CYP2B6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2B6, PROPOFOL HYDROXYLATION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN N DEMETHYLATION VIA CYP2B6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2B6, S MEPHENYTOIN N DEMETHYLATION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF AMODIAQUINE N DEETHYLATION VIA CYP2C8</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C8, AMODIAQUINE N DEETHYLATION IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF P NITROPHENOL CYP2E1 HYDROXYLATION VIA CYP2E1</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2E1, P NITROPHENOL 3 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LAURIC ACID 11 HYDROXYLATION VIA CYP2E1</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2E1, LAURIC ACID 11 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ANILINE 4 HYDROXYLATION VIA CYP2E1</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP2E1, ANILINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>ROSIGLITAZONE DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PROPOFOL HYDROXYLATION VIA CYP2B6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2B6, PROPOFOL HYDROXYLATION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN N DEMETHYLATION VIA CYP2B6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2B6, S MEPHENYTOIN N DEMETHYLATION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF P NITROPHENOL CYP2E1 HYDROXYLATION VIA CYP2E1</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2E1, P NITROPHENOL 3 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LAURIC ACID 11 HYDROXYLATION VIA CYP2E1</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2E1, LAURIC ACID 11 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ANILINE 4 HYDROXYLATION VIA CYP2E1</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2E1, ANILINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2E1, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE N DEMETHYLATION VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE 1 HYDROXYLATION VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, TACRINE 1 HYDROXYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, MIRTAZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, CLOZAPINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE CYP1A2 N DEMETHYLATION VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, CAFFEINE 3 N DEMETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF 7 ETHOXYRESORUFIN O DEETHYLATION VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, 7 ETHOXYRESORUFIN O DEETHYLATION IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE 5 HYDROXYLATION VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE 5 HYDROXYLATION IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESCITALOPRAM VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, ESCITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VENLAFAXINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, VENLAFAXINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, MIRTAZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEBRISOQUINE 4 HYDROXYLATION VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, DEBRISOQUINE 4 HYDROXYLATION IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ZOLPIDEM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ZIPRASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM 4 HYDROXYLATION VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TRIAZOLAM 4 HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TERFENADINE C HYDROXYLATION VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TERFENADINE C HYDROXYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NIFEDIPINE OXIDATION VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, NIFEDIPINE OXIDATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, MIRTAZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LOVASTATIN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, LOVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ERYTHROMYCIN N DEMETHYLATION VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ERYTHROMYCIN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN N DEMETHYLATION VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, DEXTROMETHORPHAN N DEMETHYLATION IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEHYDRO ARIPIPRAZOLE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, DEHYDRO ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, CLOZAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ARIPIPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, ALPRAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ACYCLOVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ACYCLOVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ACYCLOVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ALLOPURINOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ALLOPURINOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ALLOPURINOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ALPRAZOLAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ALPRAZOLAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMPRENAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMPRENAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>APREPITANT DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>APREPITANT DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARMODAFINIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ARMODAFINIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATAZANAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AZITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AZITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BICALUTAMIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BICALUTAMIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BOCEPREVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BOCEPREVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BUPROPION DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BUPROPION DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CAFFEINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CAFFEINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CAFFEINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CAPECITABINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CAPECITABINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CELECOXIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>CELECOXIB INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIPROFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIPROFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIPROFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIPROFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIPROFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLARITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLARITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOBAZAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOBAZAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOPIDOGREL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2B6</TD><TD>CLOPIDOGREL INHIBITS CYP2B6, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOPIDOGREL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2B6</TD><TD>CLOPIDOGREL INHIBITS CYP2B6, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CONIVAPTAN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CONIVAPTAN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>COTRIMOXAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>COTRIMOXAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CRIZOTINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CRIZOTINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CYCLOSPORINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CYCLOSPORINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DESVENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DESVENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DILTIAZEM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DILTIAZEM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DIPHENHYDRAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DIPHENHYDRAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DISULFIRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DISULFIRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DISULFIRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DRONEDARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DRONEDARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESOMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESOMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ETRAVIRINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ETRAVIRINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ETRAVIRINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ETRAVIRINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FAMOTIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FAMOTIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FAMOTIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FEBUXOSTAT DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FEBUXOSTAT DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FELBAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FELBAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVOXAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FOSAMPRENAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FOSAMPRENAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>GEMFIBROZIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>GEMFIBROZIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDRALAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDRALAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDROXYCHLOROQUINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDROXYCHLOROQUINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ILOPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ILOPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>IMATINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>IMATINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>IMATINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>IMATINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>INDINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ISONIAZID DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ISONIAZID DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ITRACONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ITRACONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>KETOCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>KETOCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>KETOCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>KETOCONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LAPATINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LAPATINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METHADONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METHADONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METHOXSALEN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METHOXSALEN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METHOXSALEN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METRONIDAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METRONIDAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MODAFINIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MODAFINIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MODAFINIL SULFONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MODAFINIL SULFONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NEFAZODONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NELFINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NELFINAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NILOTINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NILOTINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NORFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NORFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>NORFLOXACIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OXANDROLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OXANDROLONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAZOPANIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAZOPANIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAZOPANIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAZOPANIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PHENYLPROPANOLAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PHENYLPROPANOLAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PHENYLPROPANOLAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>POSACONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>POSACONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PRASUGREL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2B6</TD><TD>PRASUGREL INHIBITS CYP2B6, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PRASUGREL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2B6</TD><TD>PRASUGREL INHIBITS CYP2B6, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANITIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANITIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANITIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANITIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SERTRALINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SERTRALINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SULFINPYRAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SULFINPYRAZONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELAPREVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELAPREVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERIFLUNOMIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERIFLUNOMIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TICLOPIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TICLOPIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TICLOPIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TICLOPIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2B6</TD><TD>TICLOPIDINE INHIBITS CYP2B6, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TICLOPIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2B6</TD><TD>TICLOPIDINE INHIBITS CYP2B6, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TICLOPIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TICLOPIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TIGECYCLINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TIGECYCLINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VEMURAFENIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VEMURAFENIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VEMURAFENIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VEMURAFENIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VEMURAFENIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, ZALEPLON IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ASENAPINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, ASENAPINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VORICONAZOLE N OXIDE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZAFIRLUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, ILOPERIDONE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZAFIRLUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZAFIRLUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZAFIRLUKAST DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZILEUTON DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZIPRASIDONE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, ZIPRASIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZILEUTON DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ILOPERIDONE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, ILOPERIDONE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZILEUTON DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, ARIPIPRAZOLE IS NOT A SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZILEUTON DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSUVASTATIN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ROSUVASTATIN IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZILEUTON DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, CITALOPRAM IS NOT A SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN 4 HYDROXYLATION VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, PHENYTOIN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLURBIPROFEN 4 HYDROXYLATION VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, FLURBIPROFEN 4 HYDROXYLATION IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>